Showing 8101-8120 of 8875 for: Cochrane Systematic Reviews Back
- Three‐dimensional saline infusion sonography compared to two‐dimensional saline infusion sonography for the diagnosis of focal intracavitary lesions
Cochrane Systematic Reviews, 5-May-2017
Focal abnormalities most commonly acquired within the uterine cavity include endometrial polyps (arising from the endometrium) and submucous fibroids (arising from the myometrium). These benign abnormalities can cause several problems, including abnormal
- Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma‑induced coagulopathy in adult trauma patients with bleeding
Cochrane Systematic Reviews, 16-Feb-2015
Trauma-induced coagulopathy (TIC) is a disorder of the blood clotting process that occurs soon after trauma injury. A diagnosis of TIC on admission is associated with increased mortality rates, increased burdens of transfusion, greater risks of complicati
- Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding
Cochrane Systematic Reviews, 22-Aug-2016
Severe bleeding and coagulopathy are serious clinical conditions that are associated with high mortality. Thromboelastography (TEG) and thromboelastometry (ROTEM) are increasingly used to guide transfusion strategy but their roles remain disputed. This re
- Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke
Cochrane Systematic Reviews, 31-May-2013
Stroke is a leading cause of death and disability world wide. Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is licensed for treatment of acute ischaemic stroke in the early hours after symptom onset. It has been shown in randomised co
- Thrombolysis for acute ischaemic stroke
Cochrane Systematic Reviews, 29-Jul-2014
Most strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred and improve recovery after stroke in some people. Thrombolytic drugs, howeve
- Thrombolysis for acute upper extremity deep vein thrombosis
Cochrane Systematic Reviews, 11-Dec-2017
About 5% to 10% of all deep vein thromboses occur in the upper extremities. Serious complications of upper extremity deep vein thrombosis, such as post-thrombotic syndrome and pulmonary embolism, may in theory be avoided using thrombolysis. No systematic
- Thrombolysis for cerebral vein and dural sinus thrombosis
Cochrane Systematic Reviews, 26-Jan-2004
Treatment of cerebral sinus thrombosis with thrombolytics has been reported in cases with a deteriorating clinical course despite anticoagulant therapy. The rationale of this treatment is to promote rapid recanalisation of the occluded sinus.
- Thrombolytic agents for arterial and venous thromboses in neonates
Cochrane Systematic Reviews, 24-Jan-2005
Clinically symptomatic thromboses are infrequent but serious complications in infants undergoing intensive care. Most are related to central vascular catheters. Symptomatic thrombosis may cause severe morbidity due to irreversible organ damage and also lo
- Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb
Cochrane Systematic Reviews, 19-Jan-2021
Standard treatment for deep vein thrombosis (DVT) aims to reduce immediate complications. Use of thrombolytic clot removal strategies (i.e. thrombolysis (clot dissolving drugs), with or without additional endovascular techniques), could reduce the long-te
- Thrombolytic therapy for pulmonary embolism
Cochrane Systematic Reviews, 15-Apr-2021
Thrombolytic therapy is usually reserved for people with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE.
- Thrombophilia testing for prevention of recurrent venous thromboembolism
Cochrane Systematic Reviews, 12-Dec-2012
Tests for thrombophilia are being performed on a large scale in people after venous thromboembolism (VTE) even though the benefits of testing are still subject to debate. The most important benefit would be a reduction in the risk of recurrent VTE due to
- Thrombopoietin mimetics for patients with myelodysplastic syndromes
Cochrane Systematic Reviews, 20-Sep-2017
Myelodysplastic syndrome (MDS) is one of the most frequent haematologic malignancies of the elderly population and characterised by progenitor cell dysplasia with ineffective haematopoiesis and a high rate of transformation to acute myeloid leukaemia (AML
- Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours
Cochrane Systematic Reviews, 27-Nov-2017
Chemotherapy-induced thrombocytopenia (CIT) is defined as a peripheral platelet count less than 100×109/L, with or without bleeding in cancer patients receiving myelosuppressive chemotherapy. CIT is a significant medical problem during chemotherapy, and i
- Thromboprophylaxis for trauma patients
Cochrane Systematic Reviews, 27-Feb-2013
Trauma is a leading causes of death and disability in young people. Venous thromboembolism (VTE) is a principal cause of death. Trauma patients are at high risk of deep vein thrombosis (DVT). The incidence varies according to the method used to measure th
- Through‐knee versus above‐knee amputation for vascular and non‐vascular major lower limb amputations
Cochrane Systematic Reviews, 14-Dec-2021
Diabetes and vascular disease are the leading causes of lower limb amputation. Currently, 463 million adults are living with diabetes, and 202 million with peripheral vascular disease, worldwide. When a lower limb amputation is considered, preservation of
- Thymectomy for non-thymomatous myasthenia gravis
Cochrane Systematic Reviews, 11-Oct-2013
Treatments currently used for patients with myasthenia gravis (MG) include steroids, non-steroid immune suppressive agents, plasma exchange, intravenous immunoglobulin and thymectomy. Data from randomized controlled trials (RCTs) support the use of some o
- Thymic peptides for treatment of cancer patients
Cochrane Systematic Reviews, 16-Feb-2011
Purified thymus extracts (pTE) and synthetic thymic peptides (sTP) are thought to enhance the immune system of cancer patients in order to fight the growth of tumour cells and to resist infections due to immunosuppression induced by the disease and antine
- Thyroid hormone replacement for subclinical hypothyroidism
Cochrane Systematic Reviews, 2-Nov-2008
Subclinical hypothyroidism is defined as an elevated serum thyroid-stimulating hormone (TSH) level with normal free thyroid hormones values. The prevalence of subclinical hypothyroidism is 4% to 8% in the general population, and up to 15% to 18% in women
- Thyroid hormone supplementation for the prevention of morbidity and mortality in infants undergoing cardiac surgery
Cochrane Systematic Reviews, 13-Feb-2008
Paediatric studies have demonstrated that cardiopulmonary bypass is associated with a decline in thyroid hormone levels. Adult patients who undergo open heart surgery and receive triiodothyronine supplementation have demonstrated a dose-dependent increase
- Thyroid hormones for acute kidney injury
Cochrane Systematic Reviews, 25-Nov-2012
Acute kidney injury (AKI), which is common in hospitalised patients, is associated with significant morbidity and mortality. Despite recent advances in treatment, AKI outcomes have not changed substantially during the past four decades, and incidence is i
